Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Baxter
Boehringer Ingelheim
Moodys
Harvard Business School

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Catumaxomab

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Catumaxomab?

Catumaxomab is an investigational drug.

There have been 13 clinical trials for Catumaxomab. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2008.

The most common disease conditions in clinical trials are Ascites, Ovarian Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Neovii Biotech, Fresenius Biotech North America, and AIO-Studien-gGmbH.

Recent Clinical Trials for Catumaxomab
TitleSponsorPhase
Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian CancerJSehouliPhase 2
Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using CatumaxomabGustave Roussy, Cancer Campus, Grand ParisPhase 2
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric AdenocarcinomasNeovii BiotechPhase 2

See all Catumaxomab clinical trials

Clinical Trial Summary for Catumaxomab

Top disease conditions for Catumaxomab
Top clinical trial sponsors for Catumaxomab

See all Catumaxomab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Baxter
Johnson and Johnson
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.